Advertisement

Topics

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

10:37 EDT 19 Jun 2018 | Xconomy

Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in the broad tumor profiling panels that have struggled to gain traction but have picked up momentum recently. Roche will pay $137 per share, or $2.4 billion, for the remaining stock of Foundation (NASDAQ: FMI), […]

Original Article: In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

NEXT ARTICLE

More From BioPortfolio on "In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...